Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095 29/12/2025

68,95 USD (+0,12%)

(+0,12%) 29/12/2025

Grafiek Halozyme Therapeutics Inc.

Grafiek Halozyme Therapeutics Inc.

1 dag1d 0,12%
1 week1w 0,86%
1 maand1m 1,25%
3 maanden3m -5,99%
6 maanden6m 32,55%
1 jaar1j 43,68%
5 jaar5j 61,89%

Halozyme Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

18 december 2025 · U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer · Persbericht

16 december 2025 · Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B · Persbericht

8 december 2025 · Jim Lang Elected to Halozyme's Board of Directors · Persbericht

4 december 2025 · Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany · Persbericht

25 november 2025 · Halozyme to Participate in the 8th Annual Evercore Healthcare Conference · Persbericht

18 november 2025 · Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery · Persbericht

17 november 2025 · Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab · Persbericht

7 november 2025 · FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma · Persbericht

7 november 2025 · Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 · Persbericht

5 november 2025 · Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 · Persbericht

Profiel Halozyme Therapeutics Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe